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Summary
Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic fatty 
liver disease (NAFLD) is increasing both in Europe and the United States, becoming one of the 
most frequent causes of chronic liver disease and predictably, one of the leading causes of liver 
transplantation both for end-stage liver disease and hepatocellular carcinoma. For most transplant 
teams around the world this will raise many challenges in terms of preand post-transplant 
management. Here we review the multifaceted impact of NAFLD on liver transplantation and will 
discuss: (1) NAFLD as a frequent cause of cryptogenic cirrhosis, end-stage chronic liver disease, 
and hepatocellular carcinoma; (2) prevalence of NAFLD as an indication for liver transplantation 
both in Europe and the United States; (3) the impact of NAFLD on the donor pool; (4) the access 
of NAFLD patients to liver transplantation and their management on the waiting list in regard to 
metabolic, renal and vascular comorbidities; (5) the prevalence and consequences of post-
transplant metabolic syndrome, recurrent and de novo NAFLD; (6) the alternative management 
and therapeutic options to improve the long-term outcomes with particular emphasis on the 
correction and control of metabolic comorbidities.
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Introduction
Since its first description in the early 1980s as “a poorly understood and hitherto unnamed 
liver disease” [1], non-alcoholic fatty liver disease (NAFLD) has considerably evolved and 
progressively gained recognition among hepatologists, and has become, 30 years later, one 
of the most common causes of chronic liver disease [2–4]. Owing to its association with 
insulin resistance and metabolic risk factors, NAFLD is now considered the “hepatic 
manifestation” of metabolic syndrome (MS) and closely mirrors the global epidemics of 
obesity and type 2 diabetes [5–8]. In addition, NAFLD is the most common cause of 
elevated transaminases in the general population [2,9–11]. The prevalence of NAFLD in the 
general population ranges from 20% to 30% in Europe [12,13] and is as high as 46% in the 
United States [14]. Although initially considered as a disease of developed countries, due to 
emerging economies and adoption of a sedentary lifestyle and Western diet, the disease is 
also becoming increasingly prevalent in developing countries [11,15,16]. Nevertheless, 
because of the lack of reliable non-invasive diagnostic methods suitable for screening the 
general population, the real prevalence of NAFLD is likely still underestimated [11,17–19].
The spectrum of NAFLD covers two entities: simple steatosis and steatohepatitis (NASH), 
which is a progressive, fibrotic liver disease evolving to cirrhosis and its complications: 
hepatocellular carcinoma (HCC) and end-stage liver disease (ESLD) potentially requiring 
liver transplantation (LT). Owing to its increasing prevalence worldwide and to its 
recognition as a progressive severe liver disease, NAFLD has become the second leading 
cause of liver LT in the United States [20]. The absolute number of LT performed is roughly 
6000 per year in both Europe and the United States [21,22]. However, the frequency of 
transplant for NAFLD has steadily increased and is expected to continue to do so, while that 
for other etiologies of chronic liver disease have decreased or remained unchanged in recent 
years [20,23]. If the pool of donors decreases, these trends will probably further accentuate 
the gap between the needs of patients with ESLD and the availability of donors.
In light of the growing impact of NAFLD on all facets of LT the purpose of this review is to 
discuss NAFLD in the context of LT, with particular emphasis on its rising frequency as an 
indication for LT, the outcome and management of patients with NAFLD on the waiting list, 
its impact on the LT donor pool, short and long-term outcomes after LT for patients with 
NAFLD, and finally, optimal management options.
Before liver transplantation
NAFLD as a common cause of cryptogenic cirrhosis, end-stage liver disease and 
hepatocellular carcinoma
For many years there was no recognition of a possible link between cardiometabolic risk 
factors and the development of “cryptogenic cirrhosis”, i.e., cirrhosis without an identifiable 
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cause [24]. As a result cryptogenic cirrhosis was responsible for 3–30% of cirrhosis cases in 
the past series [25]. For the first time Powell et al. reported a gradual loss of steatosis during 
the progression of NASH towards cirrhosis, thus suggesting that some cases of 
“cryptogenic” cirrhosis may in fact be due to burned-out NASH lacking the distinctive 
steatotic features of NAFLD [26]. The demonstration that these cases of cryptogenic 
cirrhosis are bona-fide cases of advanced NASH was brought by Caldwell et al. who first 
reported a high prevalence of metabolic risk factors in these individuals [24]. The majority 
of patients initially defined as having cryptogenic cirrhosis were older females with previous 
or current history of obesity and type 2 diabetes. As the metabolic status is often modified in 
cirrhosis (altered glucose metabolism, malnutrition, ascites), it is difficult to evaluate the 
presence of concomitant metabolic risk factors. Therefore, past exposure to the metabolic 
risk factors should often be considered in cirrhotic patients. Using these criteria (either 
isolated histological features of NAFLD or past exposure to metabolic risk factors), NAFLD 
has been retrospectively identified as the underlying cause in 30%–75% of cryptogenic 
cirrhosis [24,27,28]. Supporting the hypothesis that NAFLD is a frequent cause of 
cryptogenic cirrhosis, an analysis of UNOS data between 1995 and 2005 revealed that 
during this period the proportion of NAFLD cirrhosis as an indication for LT increased from 
0.01% to 3.5% while the proportion of cryptogenic cirrhosis proportionally decreased (from 
9.6% to 6.6%). Physician awareness for NAFLD increased during the time period and more 
cases of cryptogenic cirrhosis are recognized as burned-out NASH [29].
Compared with other etiologies, NAFLD cirrhosis is diagnosed at an older age probably 
because of a slower fibrosis progression rate (on average 1 stage over 14 years) and 
decompensates later in life [30]. Due to its silent course, liver failure is often the first 
presentation at diagnosis of NAFLD-related cirrhosis (38%–45% of cases). In the early 
stages, (Child-Pugh A cirrhosis), the liver-related mortality rates are lower in NAFLD 
patients. Once cirrhosis decompensates (Child-Pugh B and C), patients with NAFLD have a 
rapidly progressive hepatic deterioration leading to similar overall and liver-related mortality 
as cirrhosis of other etiologies [31]. The main causes of death in patients with NAFLD were 
the same: infections and cirrhosis-related complications, mainly variceal hemorrhage, renal 
failure and HCC [31–33]. What differentiates the long-term prognosis of NAFLD from the 
other etiologies of cirrhosis is the cardiovascular (CV) mortality which is higher in patients 
with NAFLD [33].
A growing number of publications have linked insulin resistance, NAFLD, cryptogenic 
cirrhosis and HCC [31,34–36]. Although cirrhosis per se is a preneoplastic condition, both 
obesity and type 2 diabetes mellitus are recognized risk factors for HCC irrespective of the 
presence or the etiology of cirrhosis [36–40].
In the United States, the number of NAFLD-related HCC cases increased 9% annually 
between 2004 and 2009 [41]. In a European study, the referral for NAFLD-related HCC 
significantly increased during the same period (2005–2010) and accounted for 35% of all 
HCC recorded cases in 2010 [42]. Both American and European studies underline several 
characteristics of NAFLD-related HCC: (1) older age and higher prevalence of associated 
comorbidities; (2) occurrence in the absence of cirrhosis in 23%– 50% of cases; (3) lack of 
specific HCC surveillance in almost half of the cases; (4) more advanced stage at diagnosis, 
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and (5) less accessibility to curative therapeutic options [41–44]. As HCC specific 
surveillance has not been proven to be cost-effective and it is not recommended by the 
current guidelines in the absence of cirrhosis [45], early diagnosis of NAFLD HCC in non-
cirrhotic patients remains an unsolved issue.
NAFLD as indication for LT
The prevalence of NAFLD as an indication for LT for both ESLD and HCC has significantly 
increased both in Europe and in the United States. Based on a recent analysis of UNOS/
OPTN registry, NAFLD is now the second most common etiology of chronic liver disease 
among individuals listed for LT in the United States [21]. Remarkably, during the past 10 
years, the prevalence of NAFLD as an indication for LT has increased by 170%. During the 
same period, hepatitis C virus (HCV) and alcoholic cirrhosis as an indication for LT only 
increased by 14% and 45% respectively [20]. The percent of HCC cases attributable to 
NASH and cryptogenic cirrhosis has also significantly increased, from 8.2% in 2002 to 
13.5% in 2012. While HCV is still the primary etiology of liver disease in HCC-related LT 
recipients, NAFLD has become the second leading etiology of liver disease in HCC-related 
LT recipients [46]. Furthermore, NAFLD accounted for a significant increase in 
simultaneous liver-kidney transplantation, from 8.2% in 2002 to 22% in 2011, while the 
proportion of simultaneous liver-kidney transplantation performed for HCV/alcoholic liver 
disease (ALD) decreased from 52% to 40% in the same period [47].
In contrast to UNOS data there is less information available from the European LT Registry 
regarding NAFLD as indication for LT. A total of 145 transplant centres in 26 European 
countries have performed 93,634 LT since 1968 (mostly in France 16,366 LT, Spain 15,714 
LT, Great Britain 13,684 LT and Italy 11,697 LT) [22]. Over the last decades, alcoholic liver 
disease was the leading cause of LT (20%) followed by HCV and hepatitis B virus (HBV) 
(14% and 5%), while cryptogenic cirrhosis only accounted for 4% [22].
In the years to come, NAFLD will probably become the leading indication for LT because 
of: (1) the worldwide increasing prevalence of NAFLD paralleling the increasing prevalence 
of MS, diabetes and obesity; (2) the absence of a valid noninvasive diagnostic tool to allow 
the early diagnosis of the disease leading to the under recognition of NAFLD before the 
cirrhotic stage; (3) the absence of therapies that can effectively prevent disease progression; 
(4) the new direct-acting antiviral era and the possibility to cure HCV resulting in a 
stabilization or in a decreasing of the number of cases of HCV-related ESLD.
Outcomes of NAFLD on the waiting list for LT
Globally, patients with NAFLD on the waiting list for LT are older, have higher body mass 
index (BMI), higher prevalence of type 2 diabetes, metabolic comorbidities and lower 
glomerular filtration rate [20].
Several aspects should be particularly considered for NAFLD patients listed for LT. Morbid 
obesity (BMI ≥ 40 kg/m2) is often considered a contraindication for LT. Nevertheless, 
according to the 2013 OTPN/scientific registry of transplant patients (SRTR) annual data 
report [21], the proportion of obese (BMI ≥ 30 kg/m2) patients undergoing LT significantly 
increased over the past decade from 28% to 35.5%, with 3.6% patients having a BMI >40 
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kg/m2. While on the waiting list, patients with morbid obesity have a significantly higher 
model for end-stage liver disease (MELD) score, are less likely to be transplanted with 
MELD exception points and have a significant increase in resource utilization (altered 
functional status and physical capacity due to sarcopenic obesity, requiring hospitalization 
and specific management) [48]. Second, if listed with a MELD score of less than 15, 
NAFLD patients seem to have a longer waiting list period because of a slower disease 
progression rate (annual progression rate of 1.3 vs. 3.2 MELD points in NAFLD vs. HCV 
patients) [49]. Third, NAFLD patients are more likely to be removed from the waiting list 
because of associated comorbidities. Whereas HCV patients are removed from the waiting 
list mostly for psychological reasons and lack of social support, NAFLD patients are 
removed because of associated comorbidities, older age, impaired renal function and lower 
MELD [49]. After adjusting for MELD score, the short and long-term survival (90 day and 1 
year, respectively) on the waiting list were lower in NAFLD than in alcoholic liver disease 
[20]. Fourth, a recent analysis of UNOS/OPTN database from 2003 to 2012 found a higher 
prevalence of portal vein thrombosis in patients with NAFLD cirrhosis when compared with 
other etiologies [50]. This is probably due to a procoagulant imbalance in NAFLD patients 
[51]. Portal vein thrombosis is associated with more complicated surgical procedures, 
increased post-transplant mortality and morbidity and, if extensive, may lead to patient’s 
drop out from the waiting list for LT [52,53]. Finally, owing to excess body weight, patients 
with NAFLD are more likely to develop the “small for size syndrome” and therefore are less 
likely to be eligible for living donors and split LT. As a consequence of the above-discussed 
aspects, the 1-year probability of receiving LT is significantly lower in NAFLD (40.5%) than 
in HCV or ALD (47% for both) [20].
Impact of NAFLD on the pool of potential donors
Recent data based on expected demographic trends in the United States and past donor 
utilization indicate a further exacerbation of the donor shortage for LT [54]. Older donor 
age, higher BMI and higher prevalence of diabetes were independent predictors for declining 
liver utilization in 21% of organ donors in United States in 2010 [55]. Assuming the actual 
trends in the prevalence of diabetes and obesity, it has been estimated that the overall liver 
graft utilization in 2030 will fall from 78% to 44% [56]. As the prevalence of fatty liver is 
increasing, it is expected that a higher proportion of potential donors will have steatosis or 
steatohepatitis and might be declined for LT use. The prevalence of biopsy-proven NAFLD 
among potential living donors ranged from 15% to 53% in different studies and disqualified 
3%–21% of potential liver grafts [57].
Although an accurate assessment of liver steatosis in potential donors is required, there is no 
standard protocol for this evaluation. Some centers perform routine liver biopsy for all 
potential donors, while other centres only perform liver biopsy in selected high risk donors 
(older age, comorbidities, abnormal liver function tests). Assessment of steatosis through 
visual inspection of the graft has a positive predictive value of less than 20% for mild 
steatosis and only 70% for severe steatosis [58]. Surrogate markers of steatosis, like liver 
ultrasound coexisting with normal transaminases have also been proposed. However, among 
492 living liver donors with normal transaminases and no evidence of steatosis at ultrasound, 
the prevalence of moderate to severe steatosis was 10% and 0.6% [59]. Computed 
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tomography liver-to-spleen attenuation ratio is a reliable method to detect significant 
steatosis of >30% (sensitivity of 79% and specificity of 97%) [60]. However, these methods 
do not allow the qualitative assessment of steatosis and do not distinguish between 
microvesicular and macrovesicular steatosis.
Steatotic livers have reduced tolerance to ischemia due to lower adenosine triphosphate 
(ATP) stores and are at high risk of reperfusion injury mediated by a complex inflammatory 
response involving NFκB, Kupffer cells, cytokines and oxidative stress [61]. In contrast with 
macrovesicular steatosis, microvesicular steatosis does not have deleterious effects on graft 
survival and does not predispose to hepatic ischemia reperfusion injury [62].
Whereas liver grafts with <30% steatosis can be safely used for LT, livers with >60% 
steatosis are usually discarded because of increased probability of primary non-function 
(PNF). The use of grafts with 30–60% steatosis is controversial, as there are large 
discrepancies in reported PNF rates and 12-month graft survival [63]. In the largest study 
performed so far, macrovesicular steatosis of 20–30% in conjunction with prolonged cold 
ischemia of >11 h was an independent predictor for graft loss [64].
A recent study from Hong Kong provides insight into situations where severely steatotic 
(>60%) grafts may be used under certain conditions. Nineteen patients received severely 
steatotic grafts over a 24-year study period. There were no episodes of PNF and 1- and 3-
year survival rates were similar to the control group. MELD scores among recipients were 
low (median 20), however, and cold ischemia times were short (384 min) [65]. Whether such 
excellent outcomes are generalizable to transplants performed with higher MELD recipients 
and longer cold ischemia times is unclear.
Several strategies have been developed to optimize results when using fatty liver grafts: 
shortened ischemia time, ischemic and pharmacological preconditioning of liver grafts to 
improve microcirculation and mitochondrial function [66,67] and the use of machine-based 
liver perfusion systems [68]. In addition to improving graft preservation, hypothermic and 
normothermic machines could also promote fat loss [69]. Promising experimental results 
have been obtained with hypothermic machine perfusion [70] and several randomized 
clinical trials are now ongoing to prospectively validate their use in clinical practice 
(NCT01317342, NCT02584283, NCT01274520, clinicaltrials.gov) [71]. As highlighted by a 
recent European experience, it is likely that the impact of reconditioning severely steatotic 
grafts by machine perfusion techniques is one of the paramount challenges in LT in the very 
next future [72].
After liver transplantation
Short and long-term outcomes and overall survival
The current results of LT in general are excellent, with 1-, 3-, and 6-month survival of 94%, 
91%, and 88% respectively. The critical period after LT is the first 6 months with 49% of 
deaths and 65% of retransplantations occurring during this time interval [22].
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Obesity, type 2 diabetes and CV morbidities are frequently associated with NAFLD and may 
also have a negative impact on short and long-term outcomes after LT. There have been 
several studies reporting conflicting results on the effects of obesity on post- LT outcomes 
with some of them showing a survival benefit after LT [73,74] or combined liver-kidney 
transplantation [75] regardless of the BMI. In a recent analysis of the UNOS database from 
1987 through 2007, among 73,538 LT recipients, extreme BMI (<18.5 kg/m2 and >40 
kg/m2) was a significant predictor of death after LT [76]. Nair et al., also reported that severe 
obesity (BMI >40 kg/m2) was an independent predictor of death among 18,172 transplant 
recipients both in the postoperative period but also at 1, 3, and 5 years after LT [77]. The 
negative impact of BMI seems to be even higher in conjunction with the severity of liver 
disease or associated comorbidities. High BMI (≥ 40 kg/m2) combined with a MELD score 
≥ 22 was associated with 40% increase in mortality rate after LT [76]. In another study, 
combined obesity and type 2 diabetes was associated with a fourfold increase in the risk of 
early postoperative infections, CV events and acute renal failure, suggesting an additive 
negative impact of metabolic comorbidities [78]. Most of the studies both in Europe and US 
agree that morbid obesity increases LT resource utilization (longer operative time and 
transfusion requirements and longer intensive care unit and hospital stay) due to higher 
prevalence of early infections resulting in significantly higher costs ($134,000 for obese 
patients vs. 100,000 for non-obese patients) [77,79,80]. Because of a high prevalence of 
obesity, patients with NASH have a 50% increase in the length of hospital stay compared 
with other etiologies [81].
Long-term outcomes of LT in patients with NAFLD have been reported in several single-
centre studies or analysis of national registries. Despite increased operative difficulties and a 
higher rate of postoperative complications, the overall long-term patient and graft survival at 
1, 3, and 5 years seem to be similar to those of other indications in most studies [23,81–91] 
(Table 1). Instead, patients transplanted for NASH-HCC have decreased 5-year survival 
when compared with patients without NASH [92]. This could be due to the older age and 
more advanced stages of HCC in patients with NAFLD. Older age, BMI and associated 
metabolic comorbidities are the main modifiers of survival in NAFLD patients. Malik et al., 
described that in NAFLD patients, a BMI ≥ 30 kg/m2, together with type 2 diabetes, high 
blood pressure and age older than 60 years is associated with a one-year mortality of 50% 
after LT [82].
The main causes of death in patients with NAFLD following LT are sepsis and CV disease 
[92]. On the one hand, because of common metabolic risk factors and shared pathogenic 
pathways, patients with NAFLD have high prevalence of CV disease [93] and increased risk 
of CV mortality as compared with general population [94]. On the other hand, the 10-year 
probability for coronary heart disease and CV death is higher in LT patients as compared 
with the general population [95,96]. CV disease has emerged as the leading cause of non-
graft related mortality and accounts for 11% of deaths at 1 year among LT recipients, 
regardless the etiology of chronic liver disease [97]. In a single-centre experience at the 
Mayo Clinic, the prevalence of CV events at 1, 5, and 8 years after LT was 10%, 21%, and 
30%, with 40% of them being related to coronary artery disease and myocardial infarction 
[98]. As metabolic risk factors are still present after LT, it is expected that patients with 
NAFLD would remain at increased risk of CV disease following LT. One study reported that 
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despite similar overall mortality, patients with NAFLD are more likely to develop CV 
complications within 1 year after LT (26%), even after controlling for traditional CV risk 
factors (age, sex, smoking status, pretransplant diabetes, and CV disease) [89]. These results 
emphasize the need for an individual approach and risk stratification according to the 
etiology of chronic liver disease and associated comorbidities. Current guidelines 
recommend further CV investigations with dobutamine stress, echocardiography and 
coronary angiography in patients older than 50 years with chronic smoking history, past 
medical or family history of heart disease or type 2 diabetes [99].
Post-transplant metabolic syndrome, recurrent and de novo NAFLD
While LT treats the hepatic disease, the metabolic syndrome and associated extrahepatic 
comorbidities will obviously persist in the transplanted patient. Therefore, patients 
transplanted for NAFLD are at risk of developing recurrent NAFLD after LT, a risk that 
persists as long as the metabolic risk factors are still present. Moreover, the reversal of the 
cirrhosis-related catabolic state and the systemic effects of immunosuppressive regimens 
could promote the emergence or the worsening of metabolic abnormalities (Table 2). This 
may result in a posttransplant metabolic syndrome (PTMS) and de novo NAFLD (Fig. 1).
Post-transplant metabolic syndrome
Weight gain is common after LT and 30%–70% of patients become overweight or obese. 
The most rapid weight gain occurs in the first year following LT despite rapid tapering of 
corticosteroids: an average weight gain of 5 kg within the first year and 10 kg by 3 years 
after LT was noticed, mostly in patients older than 50 years and obese prior to LT [100]. 
Sarcopenic obesity (high fat mass and low muscle mass) after LT, owing to excess energy 
intake, decreased physical activity and older age [101], further induces insulin resistance and 
favors cardiometabolic comorbidities [102].
Because of glucose metabolism deregulation in cirrhosis, impaired glucose tolerance or type 
2 diabetes are frequent before LT. Although glycogen synthesis ameliorates after LT, only a 
minority of patients will improve insulin sensitivity. The prevalence of post-transplant new 
onset diabetes ranges between 10% and 30% and is associated with corticosteroids and 
tacrolimus use [103,104]. Dyslipidemia occurs in 40%–70% of patients, mainly in relation 
with mammalian target of rapamycin (mTOR) inhibitors. Hypertension occurs in 65% of 
patients and is mostly related with the use of calcineurin inhibitors [105].
MS occurs in 40%–50% of patients after LT, both in patients with previous NAFLD but also 
in patients undergoing LT for other etiologies of chronic liver disease [106]. The risk of 
developing MS increases by 10% for each point-increase in BMI and is closely related with 
the immunosuppressive regimen. The commonly used immunosuppressive regimens 
(calcineurin inhibitors and mTORs) have been associated with an exacerbation of 
preexisting as well as the development of de novo MS [107].
Recurrent and de novo NAFLD
NAFLD is an emerging and prevalent condition after LT either in patients transplanted for 
NAFLD or cryptogenic cirrhosis (recurrent NAFLD) or in patients undergoing LT for other 
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causes of chronic liver disease (de novo NAFLD) (Table 3). Recurrent NAFLD developed in 
30%–60% of patients following LT during a follow-up period of 1–5 years [83,108]. One 
study reported 100% recurrence of NAFLD at 5 years post-LT in 27 patients transplanted for 
NASH or cryptogenic cirrhosis [109]. Although most of these patients have mild histological 
lesions, recurrent NASH may occur in 10%–33% of patients and advanced fibrosis in 5–10% 
(Table 3) [82–84,108–112]. De novo NAFLD occurs in 20%–30% of patients, but only a 
minority (5%–10%) will develop NASH and advanced fibrosis (2%–4%) (Table 3) [113–
115]. However, most of these studies have important limitations: retrospective design, 
variable and short follow-up period, small number of patients and an important 
heterogeneity in patients’ selection and histological diagnosis of NAFLD.
Several aspects need further attention. First, it is important to identify factors associated with 
NAFLD occurrence after LT. As the pathogenesis of NAFLD is closely linked to MS and 
insulin resistance and patients transplanted for NAFLD cirrhosis already have MS before LT, 
it is expected that the recurrence rate would be much higher than the occurrence rate of de 
novo NAFLD. Most of the studies concluded that the risk of developing NAFLD after LT is 
time-dependent and closely related to the presence of the MS or its individual components. 
In one study, the recurrence rate was significantly higher (34%) in patients with PTMS 
[112]. Dumortier et al., demonstrated a dose-dependent relationship between the number of 
MS components and the risk of developing de novo NAFLD: if one, two, three, four, five, or 
six metabolic risk factors were present the proportion of patients with de novo NAFLD 
gradually increased from 12% to 22%, 29%, 65%, 81%, and 100% respectively.
Obesity and donor graft steatosis seem to be also associated with a higher risk of NAFLD 
occurrence and suggests for a role of genetic predisposition [114,115]. This hypothesis has 
been confirmed by a recent study demonstrating that recipient’s but not donor’s PNPLA3 
genotype was associated with increased risk of steatosis, supporting the role of extrahepatic 
(adipocyte) PNPLA3 activity in liver fat accumulation [116]. These results are reinforced by 
the study of Watt et al., that demonstrated that recipient but not the donor PNPLA3 genotype 
is associated with the risk of obesity and type 2 diabetes after LT [117].
Second, it is important to determine if the natural history of NAFLD is similar in pre- and 
post-transplant settings. Although direct evidence is lacking, indirect data suggest that the 
natural history of NAFLD is accelerated after LT. A minority of patients progressed from 
none to bridging fibrosis and cirrhosis in 1 or 2 years after LT outstripping the fibrosis 
progression rate from natural history studies in NAFLD patients [118].
Third, de novo and recurrent NAFLD seem to be two distinct entities with different natural 
course. A French study suggests that recurrent NAFLD is a more severe disease with an 
earlier onset than de novo NAFLD. In this study, steatosis disappeared in 22% of patients 
with de novo NAFLD and none of the patients with recurrent NAFLD, while bridging 
fibrosis occurred at 5 years in 71% of patients with recurrent NAFLD vs. 12.5% of patients 
with de novo NAFLD [119]. The fibrosis progression rate seems to be higher in patients 
with recurrent vs. de novo NAFLD, possibly in relation with a longer exposure to metabolic 
risk factors and a more severe insulin resistance. However, prospective studies with longer 
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follow-up are needed to determine the impact of recurrent and de novo NAFLD on longterm 
outcomes of patients undergoing LT.
How to optimize the outcome of NAFLD patients undergoing LT
Because of the increasing prevalence of NAFLD and its impact on LT, efforts should be 
done both to facilitate the access of patients with NAFLD to LT and to prevent them 
developing metabolic-related complications following LT.
Before liver transplantation
The first step would be to prevent NAFLD patients to develop ESLD. This requires an early 
diagnosis and appropriate therapeutic management. 10–15% of patients with NAFLD have 
cirrhosis at diagnosis, which reflect the absence of a reliable screening tool [120]. Therefore, 
it is important to increase the awareness for NAFLD and to develop reliable diagnostic and 
prognostic models to identify patients at risk for disease progression.
Unfortunately, none of the pharmacological agents now on the market proved any efficacy in 
reversing NASH or significant fibrosis. Glitazones were the most promising drugs tested so 
far in NASH, with reversal of histological features (except fibrosis) [121,122] but with a 
concern on their safety profile (weight gain and congestive heart failure) that warranted a 
black box warning. Vitamin E has also shown some efficacy in the treatment of NASH, 
however only a minority of patients studied showed histological improvements. Besides the 
long-term safety of vitamin E is also unknown [123–125]. Several promising drugs targeting 
various pathogenic pathways (farnesoid × receptor (FXR) and TGR5 – obeticholic acid, dual 
peroxisome proliferator-activated receptor alpha/delta agonists – GFT505, CCR2 – CCR5 
antagonist – cenicriviroc, anti-LOXL2 monoclonal antibodies – simtuzumab) are now in the 
pipeline and are being tested in phase IIb clinical trials, with promising effect on the reversal 
of fibrosis and resolution of NASH [126].
Second, among patients with end-stage NAFLD it is important to select those that will best 
benefit from LT. This can be challenging and different transplant centres may have different 
risk tolerances depending on transplant volume and experience. As NAFLD has only 
recently been recognized as a significant liver transplant issue, guidelines for the transplant 
assessment of the NAFLD patient have been slow to evolve. European Association for the 
Study of the Liver (EASL) recommends that MS comorbidities be assessed and controlled in 
the pre- and post-transplant setting [127]. In the American Association for the Study of 
Liver Diseases (AASLD) and American Society for Transplantation practice guidelines 
[128] for LT in adults, there are no NAFLD specific directives, other than LT is an effective 
therapy for NAFLD cirrhosis. However, many of the comorbidities found in NAFLD 
patients deserve particular attention during the evaluation.
Obesity is highly prevalent among patients with NAFLD and is considered a relative 
contraindication to transplantation [128] due to poor operative outcomes [79]. In the United 
States, Medicaid policy limits evaluation to those with a BMI less than 35 kg/m2 and many 
centres will not transplant or even evaluate patients with a BMI above 40 kg/m2 [129]. All 
obese patients (BMI >30 kg/m2) should receive dietary counselling prior to LT. Dietary and 
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lifestyle changes proved an acceptable efficacy in patients with NAFLD but the effect is 
difficult to sustain even in non-cirrhotic patients [130,131]. A small pilot study demonstrated 
that adapted physical activity may improve the index of fitness and the quality of life in 
cirrhotic patients listed for LT [132]. Additionally, weight loss may reduce portal 
hypertension as well [133]. However, if lifestyle changes alone can reverse severe cirrhotic 
NASH is still unproven.
Bariatric surgery prior to LT could be considered as it could both induce weight loss and 
improve NASH. Significant weight loss following bariatric surgery results in a reduction of 
obesity-related comorbid conditions (such as hypertension, type 2 diabetes, sleep apnea) and 
also in histological improvement in NAFLD patients [134]. In cirrhotic patients awaiting LT, 
portal hypertension is one of the major limits for bariatric surgery. In a retrospective analysis 
that included almost 4000 cirrhotic patients undergoing bariatric surgery, the mortality rates 
in patients with compensated cirrhosis were 0.9% but increased to 16% in patients with 
decompensated cirrhosis [135]. A recent study reported excellent results of combined LT 
and sleeve gastrectomy. None of the patients died or developed post- LT diabetes or steatosis 
and all have a sustained weight loss (from a mean BMI of 48 kg/m2 to a mean BMI of 29 
kg/m2) [136]. Only limited experience is available for bariatric surgery performed after LT. 
22 cases have been reported with a complication rate following the procedure of 32% and an 
overall mortality rate of 13.6% [137].
Diabetes is associated with post-transplant infections and worse patient outcomes [85,138] 
and should be optimally controlled prior to transplant. Some centres consider poorly 
controlled diabetes with end organ damage (e.g., neuropathy, retinopathy) a contraindication 
for transplantation.
Elements of the MS also increase the risk of significant coronary artery disease (CAD) and 
NAFLD itself is considered an independent risk factor for CAD and atherosclerosis 
[139,140]. The transplant evaluation requires a thorough cardiovascular work up and 
coronary stenoses >70% should be considered for revascularization [128]. A clear strategy 
for revascularization can be challenging and controversial, however. Stent placement will 
require one and occasionally two anti-platelet agents, potentially delaying transplant and 
revascularization by coronary artery bypass grafting is associated with high morbidity and 
mortality in patients with decompensated cirrhosis [141,142].
Many patients with NAFLD cirrhosis are older and while chronologic age is not a 
contraindication for LT, the physiologic age should be considered as these patients likely 
will have multiple comorbidities.
Overall it is up to the transplant centre to decide what level of risk is reasonable for patient 
and program alike, but it is nearly universally agreed that obese patients with poorly 
controlled diabetes and risk factors for CAD make poor transplant candidates.
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After liver transplantation
The present guidelines make no specific recommendation for the prevention or treatment of 
NAFLD in LT recipients other than the correction and the optimal control of individual 
components of MS and CV risk factors [99,127].
Despite an improved functional status after LT, only one quarter of patients are physically 
active [143,144]. A systematic review of randomised control trial comparing the outcomes 
of exercise training programs in solid organ recipients found no significant improvements in 
exercise capacity, CV risk factors or the incidence of new onset type 2 diabetes [145]. 
Smaller studies have shown improvements in body composition and exercise capacity when 
diet and exercise programs are initiated early after transplant [146].
Up to two-thirds of patients have increased caloric intake after LT [147] but little data are 
available about nutritional composition [146]. Nutritional interventions in the peri-operative 
time period have not demonstrated any benefits [148]. As the greatest weight gain occurs in 
the first year following LT [100], the dietary interventions should be implemented early after 
LT following the recommendations of specific guidelines for the management of overweight 
and obesity [149]. However, it makes intuitive sense that longer-term programs might be 
helpful, especially for NAFLD patients.
Because of the metabolic side effects of immunosuppressive regimens (weight gain and 
insulin resistance, hypertension, atherogenic dyslipidemia), modulating immunosuppressive 
regimens may partially avoid the PTMS and contribute to the reduction of CV risk in LT 
recipients [107]. Although there are increasing evidences that steroids avoidance and 
minimization of calcineurins inhibitors may reduce the risk of PTMS, further prospective 
studies are needed.
Conclusion
NAFLD has a multifaceted impact on LT that extends to both transplant recipients and organ 
donors. The increasing prevalence of NAFLD along with the prevalence of obesity and 
diabetes will likely result in a higher proportion of steatotic livers proposed for LT. 
Therefore, the LT community will have to face the choice of either accepting lower quality 
steatotic livers with possibly higher post-LT complication rates and inferior outcomes, or to 
discard these livers with the risk of further accentuating the shortage of the donor pool 
leading to a longer wait-list time, more complications related to ESLD on the waiting list 
and probably higher wait-list mortality. Both scenarios are likely to increase the health care 
resource utilization and costs related to LT.
NAFLD is now the second indication for LT in the United States. Following the actual trends 
in the prevalence of obesity and diabetes worldwide it is likely that NAFLD will become the 
leading cause of LT both in Europe and in United States. The long-term outcomes of patients 
transplanted for NAFLD cirrhosis are not inferior to patients transplanted for other 
etiologies. However, patients with NAFLD have some particularities – mainly older age, 
obesity and other metabolic comorbidities that most likely impact either the wait-list period 
or the short term-outcomes. Both short and long-term outcomes of patients with NAFLD are 
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marked by a higher risk to develop CV complications. Therefore, further efforts should be 
focused on the assessment and the management of NAFLD patients on the waiting list in 
order to maximize their chances to access to LT and to minimize the risk of complications 
after LT. Although LT ameliorates liver-related morbidity, as metabolic risk factors are still 
present, these patients are at increased risk of disease recurrence after LT. Further efforts 
should be done to manage and prevent the PTMS and the risk of occurrence/recurrence of 
NAFLD after LT. Long-term follow-up studies should be conducted in LT recipients to allow 
a better understanding of the mechanisms underlying the disease recurrence and to develop 
strategies to improve outcomes.
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Key point
NAFLD is becoming the leading cause of liver transplantation for both end-stage liver 
disease and hepatocellular carcinoma in the United States.
Patients with NAFLD listed for liver transplantation are more often removed from the 
waiting list because of associated comorbidities and older age.
Because of the rising prevalence of steatosis in the general population, the shortage of 
liver grafts will increase in the future. The use of fatty liver grafts will require 
optimization of surgical and graft preservation techniques.
Patients with NAFLD are at higher risk of cardiovascular morbidity and mortality 
following liver transplantation.
NAFLD recurrence is frequent after liver transplantation, mostly because of the 
persistence of metabolic risk factors. Further efforts should be done for an optimal 
control of metabolic comorbidities after liver transplantation.
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Fig. 1. 
Mechanisms and consequences of PTMS.
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Table 2
Effects of immunosuppressive regimens on PTMS components.
PTMS features Corticosteroids Calcineurin inhibitors mTOR inhibitors
(sirolimus, everolimus)
Tacrolimus Cyclosporine
Abdominal obesity + − − −
New-onset diabetes +++ ++ + −
Dyslipidemia + + + +++
Hypertension + ++ ++ +
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